Many Big Winners Are Among  Rayno Diagnostics and Tools Stocks in 2014

Abaxis (ABAX) up 46%  A major “Point of Care” (POC) Dx Player in veterinary and human markets.

Exact Sciences (EXAS) up 135%  An emerging Dx player with non-invasive, DNA based test for colon cancer.

Illumina Inc. (ILMN) up 68%  Leading provider of DNA sequencing tools with new paradigm for diagnostics.

Pacific Biosciences (PACB) up 42.6% Emerging DNA sequencing player.

Sequenom (SQNM) up 53.4% Genetic analysis (SNPs) for prenatal testing  and other diseases. Spun off bioscience division.

Despite growth of only ~2% in the ~$55B clinical diagnostic market Worldwide in 2013 , new technologies such as sequencing and market niches like POC (Point of Care) and immunoassays provide revenue growth. LDTs (Lab Developed Tests) are also a growth area but the FDA will soon be issuing guidelines for these tests which have limited clinical diagnostic use. Also the FDA will have a public workshop on February 20 on the use of NGS (Next Generation Sequencing) tests. The veterinary market segment has also been a high growth area.

Molecular testing has been a high growth market for several years so that now there are 150 players including the leaders Abbott (ABT), Roche (RHHBY), and ThermoFisher (TMO). See IVD News for more details.

We will review all of our portfolio picks after the 2014 Financial Results. We made two new Dx picks in H2 2014: Foundation Medicine (FMI) at $25 and Pacific Biosciences of California (PACB) at $5.75.

Sign up now to receive 2015 updates on this important sector with a lot of new coming in early 2015.

Here is the complete Rayno Portfolio Summary with April and November Updates:

Diagnostics and Tools Stocks Sold-Off in Q1 But Long Term Outlook Attractive |

Pin It on Pinterest